Optimal Timing of Simethicone Supplement for Bowel Preparation: A Prospective Randomized Controlled Trial

Table 3

Colonoscopy outcomes.

	SIM evening group (n = 208)	SIM morning group (n = 211)	value
Diagnosis, n (%)
Adenoma	71 (34.1%)	65 (30.8%)	0.47^a
Adenocarcinoma	0 (0%)	2 (0.9%)	0.97^a
Neuroendocrine tumor	1 (0.5%)	1 (0.5%)	0.499^a
Hyperplastic polyps	20 (9.6%)	18 (8.5%)	0.699^a
IBD	5 (2.4%)	4 (1.9%)	0.75^a
Chronic enteritis	6 (2.9%)	7 (3.3%)	0.798^a
Normal	95 (45.7%)	108 (51.2%)	0.259^a
Total adenomas	154	153	—
Right colon	48 (31.2%)	44 (28.8%)	0.62^a
Transverse colon	41 (26.6%)	47 (30.7%)	0.43^a
Left colon	65 (42.2%)	62 (40.5%)	0.76^a
Right colon
≤5 mm	30 (62.5%)	17 (38.6%)	0.022^a
5–10 mm	11 (22.9%)	15 (34.1%)	0.23^a
≥10 mm	7 (14.6%)	12 (27.3%)	0.13^a
Transverse colon
≤5 mm	20 (48.8%)	22 (46.8%)	0.85^a
5–10 mm	9 (22.0%)	11 (23.4%)	0.87^a
≥10 mm	12 (29.2%)	14 (29.8%)	0.96^a
Left colon
≤5 mm	31 (47.7%)	30 (48.4%)	0.94^a
5–10 mm	21 (32.3%)	22 (35.5%)	0.71^a
≥10 mm	13 (20.0%)	10 (16.1%)	0.57^a
Cecal intubation time (minutes)	3.80 ± 1.81	4.42 ± 2.03	<0.001^b
Withdrawal time (minutes)	8.22 ± 2.04	8.01 ± 2.51	0.094^b

Note. IBD, inflammation bowel disease; a, Bonferroni method χ2 test; b, Student’s t-test.